Adults 12 to 17, any sex, with Anorexia Nervosa or Atypical Anorexia Nervosa. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
CriticismPrimary· baseline, 1-month (halfway through the 10-session emotion coaching intervention), post-treatment, and 3-month follow- up
Parent Criticism was assessed by the Five Minute Speech Sample. This is a recorded five-minute unstructured response that the parent gives when prompted to talk about their feelings about their child. Eligible families will be categorized as high expressed emotion using a modified version of the Family Affective Attitudes Rating Scale (FAARS), which was developed to code the Five Minute Speech Sample in families with adolescents. Scores on Criticism range from 1-9 with higher scores reflective of greater parent criticism towards their adolescent (worse outcome).
1-Month
Group
Value
95% CI
Emotion Coaching
5.5
± 2.8
Support Group
3.7
± 2.1
Post-Treatment
Group
Value
95% CI
Emotion Coaching
3.7
± 2.0
Support Group
4.3
± 2.1
3 Month Follow-Up
Group
Value
95% CI
Emotion Coaching
2.6
± 1.6
Support Group
3.1
± 2.0
Percent Expected Body Weight (%EBW)Primary· baseline, 1-month, post-treatment, and 3-month follow up
Percent Expected Body Weight is the current weight divided by the adolescent's Expected Body Weight based on their premorbid body mass index percentile for age-and-sex (Body Mass Index Percentile; Centers for Disease Control and Prevention, 2000). Expected Body Weights were calculated by research team members to ensure a standardized calculation methodology. One research team member extracted the highest and lowest premorbid Body Mass Index Percentile from each participant's medical chart and calculated the mean premorbid Body Mass Index Percentile, and Percent Expected Body Weight (i.e., curr
1-Month
Group
Value
95% CI
Emotion Coaching
95.1
± 7.1
Support Group
90.8
± 7.8
Post-Treatment
Group
Value
95% CI
Emotion Coaching
96.6
± 6.3
Support Group
92.5
± 8.3
3 Month Follow-up
Group
Value
95% CI
Emotion Coaching
98.0
± 5.6
Support Group
92.6
± 10.4
Parental WarmthSecondary· baseline, 1-month, post-treatment, and 3 month follow-up
Parental Warmth was assessed by the Five Minute Speech Sample. This is a recorded five-minute unstructured response that the parent gives when prompted to talk about their feelings about their child. Eligible families will be categorized as high expressed emotion using a modified version of the Family Affective Attitudes Rating Scale (FAARS), which was developed to code the Five Minute Speech Sample in families with adolescents. Scores on Warmth range from 1-9 with higher scores reflective of greater parent warmth towards their adolescent (better outcome).
1-Month
Group
Value
95% CI
Emotion Coaching
7.0
± 1.3
Support Group
6.3
± 1.8
Post-Treatment
Group
Value
95% CI
Emotion Coaching
7.8
± 0.6
Support Group
5.5
± 1.9
3 Month Follow-Up
Group
Value
95% CI
Emotion Coaching
7.4
± 1.7
Support Group
7.5
± 1.6
Adverse events — posted to ClinicalTrials.gov
Time frame: Each adolescent participant was in the study for a duration of 6 months (from consent until follow up assessment)..
Reporting threshold: 1%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Family based treatment (FBT) is the evidence based treatment for pediatric anorexia nervosa (AN), but 50% of adolescents do not respond and the consequences for non-response are dire (e.g., 11.5% mortality rate). Expressed emotion and parental warmth are significant mechanisms of treatment outcome in adolescents with AN, which are not explicitly targeted by FBT. The current proposal is a parent emotion coaching skills group designed to augment FBT in the treatment of pediatric AN by arming high expressed emotion families with the skills necessary to implement FBT and improve treatment outcomes (e.g., weight restoration).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young
· Phase 2
· recruiting
NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders
· NA
· recruiting
NCT07188155 — Adapting Exposure for Adolescent AN
· NA
· recruiting
NCT07143981 — The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa
· recruiting
NCT07311356 — Prognosis of Early-onset Anorexia Nervosa
· recruiting
Other Children's Hospital Medical Center, Cincinnati trials
Trials by the same sponsor.
NCT07430332 — GLP-1 RA for Stage 1 Type 1 Diabetes
· Phase 2
· not yet recruiting
NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
· recruiting
NCT07265141 — An Automated Virtual Reality Intervention to Enhance Firearm Safety Counseling in Pediatrics
· NA
· not yet recruiting
NCT07217444 — Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
· NA
· recruiting
NCT07195123 — Evaluation of the SMART IBD App in Pediatric IBD
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Hospital Medical Center, Cincinnati
Last refreshed: 26 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04421989.